151751-Najiba-Chargi

62 CHAPTER 4 Table 1. (Continued) Characteristics All patients (n = 113) N (%) or Mean (±SD) Normal MSMI (n = 84) N (%) or Mean (±SD) Low MSMI (n = 29) N (%) or Mean (±SD) p-value T-staging 0.2 T0 1 (0.9) 1 (1.2) 0 (0.0) T1 21 (18.6) 17 (20.2) 4 (13.8) T2 37 (32.7) 29 (34.5) 8 (27.6) T3 24 (21.2) 16 (19.0) 8 (27.6) T4a,b 29 (25.7) 20 (23.8) 9 (31.0) Tx 1 (0.9) 1 (1.2) 0 (0.0) N-staging 0.6 N0 44 (38.9) 33 (39.3) 11 (37.9) N1 18 (15.9) 13 (15.5) 5 (17.2) N2a,b,c 50 (50.3) 37 (44.0) 13 (44.9) N3 1 (0.9) 1 (1.2) 0 (0.0) M-staging M0 104 (92.0) 78 (92.9) 26 (89.7) 0.4 M1 2 (1.8) 2 (2.4) 0 (0.0) Mx 7 (6.2) 4 (4.8) 3 (10.3) Tumor, Node, Metastasis (TNM) stage 0.9 Stage I 4 (3.5) 3 (3.6) 1 (3.4) Stage II 18 (15.9) 14 (16.7) 4 (13.8) Stage III 20 (17.7) 16 (19.0) 4 (13.8) Stage IV 71 (62.8) 51 (60.7) 20 (69.0) Treatment modality 0.4 Surgery with or without (chemo)radiotherapy 34 (30.1) 28 (33.3) 6 (20.7) Radiotherapy 26 (23.0) 18 (21.4) 8 (27.6) Radiotherapy with concurrent cisplatin, carboplatin or cetuximab 53 (46.9) 38 (45.2) 15 (51.7) Comparison of patient characteristics based on MSMI classification. Statistically significant differences are shown in bold. BODY COMPOSITION MEASUREMENT Table 2 shows a significant difference based on gender for BMI (p=0.02), BSA, L3 CSA, C3 CSA, MCSA, MV, MT, L3 SMI and MSMI (all p<0.001). There was no significant difference based on gender for HU tot and HU ROI (Table 2).